anurajms/meta_analysis huggingface dataset:
MESH terms:
Penile rehabilitation for postprostatectomy erectile dysfunction
1. Alprostadil [administration & dosage]; 2. Drug Administration Schedule; 3. Erectile Dysfunction [etiology, *rehabilitation]; 4. Penile Erection [*physiology]; 5. Phosphodiesterase 5 Inhibitors [adverse effects, therapeutic use]; 6. Postoperative Complications [*rehabilitation]; 7. Prostatectomy [adverse effects, *rehabilitation]; 8. Prostatic Neoplasms [*surgery]; 9. Quality of Life; 10. Surveys and Questionnaires; 11. Urological Agents [administration & dosage]; 12. Withholding Treatment [statistics & numerical data];
MESH terms:
Intrauterine administration of human chorionic gonadotropin (hCG) for subfertile women undergoing assisted reproduction
1. *Embryo Transfer [adverse effects, statistics & numerical data]; 2. Abortion, Spontaneous [epidemiology, etiology]; 3. Chorionic Gonadotropin [*administration & dosage]; 4. Embryo Implantation [drug effects]; 5. Infertility, Female [*drug therapy]; 6. Live Birth [epidemiology]; 7. Pregnancy Rate; 8. Reproductive Control Agents [*administration & dosage]; 9. Uterus;
MESH terms:
Vasodilators for women undergoing fertility treatment
1. Embryo Implantation [*drug effects]; 2. Infertility, Female [*therapy]; 3. Live Birth; 4. *Pregnancy Rate; 5. Randomized Controlled Trials as Topic; 6. Vasodilator Agents [*therapeutic use];
MESH terms:
Pain relief for women undergoing oocyte retrieval for assisted reproduction
1. *Fertilization in Vitro; 2. Analgesia [*methods]; 3. Anesthesia, General; 4. Conscious Sedation [*methods]; 5. Electroacupuncture; 6. Oocyte Retrieval [adverse effects, *methods]; 7. Pain Measurement; 8. Pain, Procedural [*therapy]; 9. Pregnancy Outcome; 10. Pregnancy Rate; 11. Randomized Controlled Trials as Topic;
MESH terms:
Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer)
1. Abortion, Spontaneous [*epidemiology]; 2. *Embryo Transfer; 3. Fertilization in Vitro; 4. *Genitalia, Female; 5. Live Birth [*epidemiology]; 6. Pregnancy Rate; 7. Pregnancy, Ectopic [epidemiology]; 8. Pregnancy, Multiple; 9. Publication Bias; 10. Randomized Controlled Trials as Topic; 11. Reproductive Techniques, Assisted; 12. *Semen [physiology]; 13. Sperm Injections, Intracytoplasmic;
MESH terms:
Anti‐adhesion therapy following operative hysteroscopy for treatment of female subfertility
1. Amnion [transplantation]; 2. Estrogens [therapeutic use]; 3. Gels [therapeutic use]; 4. Hysteroscopy [*adverse effects]; 5. Infertility, Female [*surgery]; 6. Intrauterine Devices; 7. Live Birth [epidemiology]; 8. Randomized Controlled Trials as Topic; 9. Second‐Look Surgery [statistics & numerical data]; 10. Tissue Adhesions [epidemiology, etiology, therapy]; 11. Uterine Diseases [epidemiology, etiology, *therapy];
MESH terms:
Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation
1. Clomiphene [*administration & dosage]; 2. Drug Therapy, Combination [methods]; 3. Fertility Agents, Female [*administration & dosage]; 4. Fertilization in Vitro [*methods]; 5. Gonadotropin‐Releasing Hormone [antagonists & inhibitors]; 6. Gonadotropins [*administration & dosage]; 7. Letrozole; 8. Live Birth [epidemiology]; 9. Nitriles [*administration & dosage]; 10. Oocyte Retrieval [statistics & numerical data]; 11. Ovarian Hyperstimulation Syndrome [chemically induced, epidemiology]; 12. Ovulation Induction [*methods]; 13. Pregnancy Rate; 14. Randomized Controlled Trials as Topic; 15. Sperm Injections, Intracytoplasmic; 16. Triazoles [*administration & dosage];
MESH terms:
Pain relief for outpatient hysteroscopy
1. Ambulatory Surgical Procedures [*adverse effects]; 2. Analgesia [*methods]; 3. Anesthetics, Local [*therapeutic use]; 4. Hysteroscopy [*adverse effects]; 5. Pain, Postoperative [*drug therapy];
MESH terms:
Cycle regimens for frozen‐thawed embryo transfer
1. *Estrogens; 2. *Pregnancy Rate; 3. *Progesterone; 4. Clomiphene; 5. Cryopreservation; 6. Embryo Transfer [*methods]; 7. Endometrium [*drug effects, physiology]; 8. Fertility Agents, Female; 9. Follicular Phase [drug effects, physiology]; 10. Gonadotropin‐Releasing Hormone [agonists]; 11. Ovulation Induction [*methods]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles
1. Abortion, Spontaneous [epidemiology]; 2. Drug Therapy, Combination; 3. Fertilization in Vitro [methods]; 4. Follicle Stimulating Hormone [*administration & dosage]; 5. Live Birth [epidemiology]; 6. Luteinizing Hormone [*administration & dosage]; 7. Ovarian Hyperstimulation Syndrome [chemically induced]; 8. Ovulation Induction [*methods]; 9. Pregnancy Rate; 10. Randomized Controlled Trials as Topic; 11. Recombinant Proteins [administration & dosage]; 12. Sperm Injections, Intracytoplasmic;
MESH terms:
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome
1. *Chorionic Gonadotropin; 2. Abortion, Spontaneous [epidemiology]; 3. Cabergoline; 4. Ergolines; 5. Fertilization in Vitro; 6. Follicle Stimulating Hormone [administration & dosage, adverse effects]; 7. Gonadotropin‐Releasing Hormone [antagonists & inhibitors]; 8. Live Birth [epidemiology]; 9. Ovarian Hyperstimulation Syndrome [epidemiology, etiology, *prevention & control]; 10. Pregnancy Rate; 11. Pregnancy, Multiple [statistics & numerical data]; 12. Randomized Controlled Trials as Topic; 13. Withholding Treatment;
MESH terms:
Septum resection for women of reproductive age with a septate uterus
1. Abortion, Habitual [*therapy]; 2. Hysteroscopy; 3. Uterus [*abnormalities, *surgery];
MESH terms:
Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome
1. Anovulation [*complications, drug therapy]; 2. Clomiphene [adverse effects, *therapeutic use]; 3. Contraceptives, Oral, Combined [therapeutic use]; 4. Dexamethasone [therapeutic use]; 5. Drug Therapy, Combination [methods]; 6. Estrogen Antagonists [adverse effects, *therapeutic use]; 7. Gonadotropins [therapeutic use]; 8. Infertility, Female [*drug therapy, etiology]; 9. Live Birth; 10. Polycystic Ovary Syndrome [complications]; 11. Randomized Controlled Trials as Topic; 12. Tamoxifen [therapeutic use];
MESH terms:
Day three versus day two embryo transfer following in vitro fertilization or intracytoplasmic sperm injection
1. *Embryo Transfer; 2. *Fertilization in Vitro; 3. *Sperm Injections, Intracytoplasmic; 4. Abortion, Spontaneous [epidemiology]; 5. Embryonic Development; 6. Live Birth [epidemiology]; 7. Oocyte Retrieval; 8. Pregnancy Outcome; 9. Pregnancy Rate; 10. Randomized Controlled Trials as Topic; 11. Time Factors;
MESH terms:
Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation
1. Abortion, Spontaneous [epidemiology]; 2. Chorionic Gonadotropin [*administration & dosage, adverse effects]; 3. *In Vitro Oocyte Maturation Techniques; 4. *Infertility, Female; 5. Live Birth [epidemiology]; 6. Oocyte Retrieval; 7. *Pregnancy Rate; 8. Randomized Controlled Trials as Topic; 9. Reproductive Control Agents [*administration & dosage, adverse effects];
MESH terms:
Aspirin for in vitro fertilisation
1. *Fertilization in Vitro; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage]; 3. Aspirin [*administration & dosage]; 4. Cyclooxygenase Inhibitors [*administration & dosage]; 5. Live Birth; 6. Platelet Aggregation Inhibitors [*administration & dosage]; 7. Pregnancy Outcome; 8. Pregnancy Rate; 9. Randomized Controlled Trials as Topic;
MESH terms:
Volume expanders for the prevention of ovarian hyperstimulation syndrome
1. Fertilization in Vitro; 2. Hydroxyethyl Starch Derivatives [*administration & dosage]; 3. Injections, Intravenous; 4. Ovarian Hyperstimulation Syndrome [*prevention & control]; 5. Plasma Substitutes [*administration & dosage]; 6. Pregnancy Rate; 7. Randomized Controlled Trials as Topic; 8. Serum Albumin [*administration & dosage]; 9. Sperm Injections, Intracytoplasmic;
MESH terms:
Progestin‐only contraceptives: effects on weight
1. Body Composition [drug effects]; 2. Body Weight [*drug effects]; 3. Contraceptives, Oral, Hormonal [pharmacology]; 4. Drug Implants; 5. Intrauterine Devices, Medicated; 6. Levonorgestrel [*pharmacology]; 7. Medroxyprogesterone Acetate [*pharmacology]; 8. Progestins [*pharmacology]; 9. Prospective Studies; 10. Retrospective Studies; 11. Weight Gain [drug effects];
MESH terms:
Hormonal contraceptives for contraception in overweight or obese women
1. *Body Mass Index; 2. *Obesity; 3. *Pregnancy Rate; 4. Body Weight; 5. Contraception [*methods]; 6. Contraceptive Agents, Female [*administration & dosage]; 7. Overweight; 8. Pregnancy, Unplanned; 9. Prospective Studies; 10. Randomized Controlled Trials as Topic;
MESH terms:
Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
1. *Reproductive Techniques, Assisted; 2. Gonadotropin‐Releasing Hormone [agonists, *antagonists & inhibitors]; 3. Live Birth; 4. Ovarian Hyperstimulation Syndrome [prevention & control]; 5. Ovulation Induction [methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles
1. Chorionic Gonadotropin [*therapeutic use]; 2. Fertilization in Vitro; 3. Gonadotropin‐Releasing Hormone [agonists]; 4. Luteinizing Hormone [*therapeutic use]; 5. Ovulation Induction [*methods]; 6. Randomized Controlled Trials as Topic; 7. Recombinant Proteins [therapeutic use]; 8. Sperm Injections, Intracytoplasmic;
MESH terms:
Psychological and educational interventions for subfertile men and women
1. Anxiety [*therapy]; 2. Depression [*therapy]; 3. Infertility [*psychology, *therapy]; 4. Live Birth; 5. Patient Dropouts [statistics & numerical data]; 6. Pregnancy Rate; 7. Reproductive Techniques, Assisted; 8. Stress, Psychological [*therapy]; 9. Treatment Outcome;
MESH terms:
Brief educational strategies for improving contraception use in young people
1. Condoms; 2. Contraception [*methods]; 3. Contraceptive Agents [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Sex Education [*methods];
MESH terms:
Ultrasound versus 'clinical touch' for catheter guidance during embryo transfer in women
1. *Ultrasonography, Interventional; 2. Embryo Transfer [adverse effects, *methods]; 3. Palpation [adverse effects, *methods]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Assisted reproductive technologies for male subfertility
1. *Birth Rate; 2. *Coitus; 3. *Fertilization; 4. *Infertility, Male; 5. *Ovulation Induction; 6. Insemination, Artificial [*methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Culture media for human pre‐implantation embryos in assisted reproductive technology cycles
1. *Culture Media [adverse effects]; 2. *Embryo, Mammalian; 3. *Fertilization in Vitro; 4. *Oocytes; 5. *Sperm Injections, Intracytoplasmic; 6. Abortion, Spontaneous; 7. Embryo Transfer; 8. Live Birth; 9. Pregnancy Rate; 10. Pregnancy, Multiple; 11. Randomized Controlled Trials as Topic;
MESH terms:
Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction
1. *Reproductive Techniques, Assisted; 2. Buserelin [administration & dosage]; 3. Clinical Protocols; 4. Drug Administration Schedule; 5. Fertility Agents, Female [*administration & dosage]; 6. Gonadotropin‐Releasing Hormone [*agonists]; 7. Leuprolide [administration & dosage]; 8. Live Birth [epidemiology]; 9. Luteinizing Hormone [*antagonists & inhibitors, metabolism]; 10. Ovulation Induction [*methods]; 11. Pituitary Gland [*drug effects]; 12. Pregnancy Rate; 13. Randomized Controlled Trials as Topic; 14. Triptorelin Pamoate [administration & dosage];
MESH terms:
Lactational amenorrhoea method for family planning
1. *Amenorrhea; 2. *Breast Feeding; 3. *Contraception Behavior; 4. *Postpartum Period; 5. Contraception [*methods]; 6. Family Planning Services; 7. Lactation; 8. Life Tables; 9. Menstruation; 10. Pregnancy Rate;
MESH terms:
Pain relief in hysterosalpingography
1. Analgesia [*methods]; 2. Analgesics, Non-Narcotic [therapeutic use]; 3. Analgesics, Opioid [therapeutic use]; 4. Hysterosalpingography [*adverse effects]; 5. Infertility, Female [etiology]; 6. Nerve Block [methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Luteal phase support for assisted reproduction cycles
1. *Reproductive Techniques, Assisted; 2. Chorionic Gonadotropin [adverse effects, *therapeutic use]; 3. Drug Therapy, Combination; 4. Estrogens [*therapeutic use]; 5. Gonadotropin‐Releasing Hormone [*agonists]; 6. Live Birth [epidemiology]; 7. Luteal Phase [*drug effects, physiology]; 8. Ovarian Hyperstimulation Syndrome [chemically induced]; 9. Pregnancy Maintenance [drug effects]; 10. Progesterone [*therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility
1. *Pregnancy Rate; 2. Embryo Transfer; 3. Fertilization in Vitro [*methods]; 4. Infertility, Female [*therapy]; 5. Oocyte Retrieval; 6. Ovarian Cysts [*therapy]; 7. Ovarian Follicle; 8. Ovulation Induction [methods]; 9. Randomized Controlled Trials as Topic; 10. Suction [adverse effects, *methods]; 11. Ultrasonography, Interventional;
MESH terms:
Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology
1. *Fertilization in Vitro; 2. *Sperm Injections, Intracytoplasmic; 3. Chorionic Gonadotropin [*therapeutic use]; 4. Gonadotropin‐Releasing Hormone [*agonists]; 5. Oocyte Donation [methods]; 6. Oocytes [drug effects, growth & development]; 7. Ovarian Hyperstimulation Syndrome [epidemiology]; 8. Ovulation Induction [*methods]; 9. Pregnancy Rate; 10. Randomized Controlled Trials as Topic;
MESH terms:
Vitrification versus slow freezing for women undergoing oocyte cryopreservation
1. *Freezing; 2. *Oocytes; 3. *Pregnancy Rate; 4. *Vitrification; 5. Cryopreservation [*methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Surgical intervention versus expectant management for endometrial polyps in subfertile women
1. Infertility, Female [etiology, *surgery]; 2. Polyps [complications, *surgery]; 3. Randomized Controlled Trials as Topic; 4. Uterine Diseases [complications, *surgery]; 5. *Watchful Waiting;
MESH terms:
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
1. Contraceptives, Oral, Combined [*pharmacology]; 2. Contraceptives, Oral, Hormonal [*pharmacology]; 3. Dietary Carbohydrates [*metabolism]; 4. Fasting [blood]; 5. Glucose [*metabolism]; 6. Insulin [metabolism]; 7. Insulin Resistance [physiology]; 8. Overweight [metabolism]; 9. Progestins [pharmacology]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Oral contraceptives for functional ovarian cysts
1. Contraceptives, Oral, Combined [*therapeutic use]; 2. Ovarian Cysts [*drug therapy]; 3. Randomized Controlled Trials as Topic; 4. Remission Induction; 5. Remission, Spontaneous; 6. Watchful Waiting;
MESH terms:
Combination contraceptives: effects on weight
1. Administration, Cutaneous; 2. Body Weight [*drug effects]; 3. Contraceptive Agents, Female [administration & dosage, *adverse effects]; 4. Contraceptives, Oral, Combined [adverse effects]; 5. Contraceptives, Oral, Hormonal [adverse effects]; 6. Randomized Controlled Trials as Topic; 7. Weight Gain;
MESH terms:
Heparin for assisted reproduction
1. *Birth Rate; 2. *Embryo Implantation; 3. *Live Birth; 4. *Reproductive Techniques, Assisted; 5. Anticoagulants [*administration & dosage, adverse effects]; 6. Drug Administration Schedule; 7. Embryo Transfer; 8. Heparin, Low‐Molecular‐Weight [*administration & dosage, adverse effects]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Exercise as adjunctive therapy for systemic lupus erythematosus
1. *Exercise; 2. Exercise Therapy [methods]; 3. Fatigue [etiology, therapy]; 4. *Lupus Erythematosus, Systemic [complications, therapy]; 5. Pain; 6. Quality of Life;
MESH terms:
Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee
1. Exercise Therapy; 2. *Osteoarthritis, Hip [therapy]; 3. *Osteoarthritis, Knee [therapy]; 4. Pain; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic;
MESH terms:
Stem cell transplantation for systemic sclerosis
1. Cyclophosphamide [therapeutic use]; 2. *Hematopoietic Stem Cell Transplantation; 3. Randomized Controlled Trials as Topic; 4. *Scleroderma, Systemic [therapy];
MESH terms:
Dietary supplements for chronic gout
1. Allopurinol; 2. Dietary Supplements; 3. *Gout [drug therapy]; 4. Milk; 5. Powders;
MESH terms:
Autologous blood and platelet‐rich plasma injection therapy for lateral elbow pain
1. Arthroscopy; 2. *Elbow; 3. Pain Measurement; 4. *Platelet-Rich Plasma; 5. Shoulder Pain;
MESH terms:
Colchicine for acute gout
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; 2. *Colchicine [adverse effects]; 3. Glucocorticoids [therapeutic use]; 4. *Gout [drug therapy]; 5. Pain [drug therapy];
MESH terms:
Tramadol for osteoarthritis
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Arthritis, Rheumatoid [drug therapy]; 3. Drug Therapy, Combination; 4. Osteoarthritis [*complications, drug therapy]; 5. Osteoarthritis, Knee [drug therapy]; 6. Pain [*drug therapy, etiology, prevention & control]; 7. Pain Management; 8. Pain Measurement; 9. Tramadol [*therapeutic use];
MESH terms:
Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
1. Antibodies, Monoclonal, Humanized; 2. Antirheumatic Agents [*therapeutic use]; 3. Arthritis, Rheumatoid [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Receptors, Tumor Necrosis Factor [*therapeutic use]; 6. Recurrence; 7. Remission Induction; 8. Tumor Necrosis Factor-alpha [*antagonists & inhibitors];
MESH terms:
Methotrexate for psoriatic arthritis
1. Administration, Oral; 2. Antirheumatic Agents [*administration & dosage, adverse effects]; 3. Dermatologic Agents [*administration & dosage, adverse effects]; 4. Methotrexate [*administration & dosage, adverse effects]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Exercise for rheumatoid arthritis of the hand
1. *Hand; 2. Arthritis, Rheumatoid [*therapy]; 3. Exercise Therapy [adverse effects, *methods]; 4. Hand Strength; 5. Pain Measurement [methods]; 6. Randomized Controlled Trials as Topic; 7. Time Factors; 8. Treatment Outcome;
MESH terms:
Exercise interventions and patient beliefs for people with hip, knee or hip and knee osteoarthritis: a mixed methods review
1. *Health Knowledge, Attitudes, Practice; 2. Anxiety [rehabilitation]; 3. Arthralgia [*rehabilitation]; 4. Chronic Pain [psychology, rehabilitation]; 5. Depression [rehabilitation]; 6. Exercise Therapy [*psychology]; 7. Osteoarthritis, Hip [*psychology, *rehabilitation]; 8. Osteoarthritis, Knee [*psychology, *rehabilitation]; 9. Qualitative Research; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Self Efficacy; 13. Social Participation; 14. Symptom Assessment;
MESH terms:
Surgery for trigger finger
1. Hyaluronic Acid [administration & dosage]; 2. Injections, Intra‐Articular [adverse effects]; 3. Pain, Postoperative [etiology]; 4. Recurrence; 5. Steroids [administration & dosage]; 6. Treatment Outcome; 7. Trigger Finger Disorder [drug therapy, *surgery];
MESH terms:
Back Schools for chronic non‐specific low back pain
1. Chronic Pain [*therapy]; 2. Disability Evaluation; 3. Exercise Therapy [*methods]; 4. Low Back Pain [*therapy]; 5. Pain Measurement; 6. Patient Education as Topic [*methods, organization & administration]; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Celecoxib for rheumatoid arthritis
1. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 2. Arthritis, Rheumatoid [*drug therapy]; 3. Celecoxib [adverse effects, *therapeutic use]; 4. Myocardial Infarction [chemically induced, epidemiology]; 5. Pain Measurement; 6. Randomized Controlled Trials as Topic; 7. Stomach Ulcer [chemically induced, epidemiology]; 8. Stroke [chemically induced, epidemiology]; 9. Treatment Outcome;
MESH terms:
Celecoxib for osteoarthritis
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects, *therapeutic use]; 2. Celecoxib [adverse effects, *therapeutic use]; 3. Diclofenac [therapeutic use]; 4. Naproxen [therapeutic use]; 5. Osteoarthritis, Hip [*drug therapy]; 6. Osteoarthritis, Knee [*drug therapy]; 7. Pain Measurement [methods]; 8. Placebos [adverse effects, therapeutic use]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
Exercise for hand osteoarthritis
1. *Exercise Therapy [adverse effects]; 2. *Hand Joints; 3. Arthralgia [etiology, *therapy]; 4. Finger Joint; 5. Hand Strength [physiology]; 6. Osteoarthritis [*therapy]; 7. Pain Measurement; 8. Patient Dropouts; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Self Report;
MESH terms:
Stretch for the treatment and prevention of contractures
1. *Range of Motion, Articular; 2. Contracture [prevention & control, *therapy]; 3. Joints; 4. Muscle Stretching Exercises [*methods]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Time Factors;
MESH terms:
Surgical options for lumbar spinal stenosis
1. *Lumbar Vertebrae; 2. Back Pain [surgery]; 3. Blood Loss, Surgical [statistics & numerical data]; 4. Decompression, Surgical [*methods]; 5. Leg; 6. Operative Time; 7. Pain Management; 8. Randomized Controlled Trials as Topic; 9. Reoperation [statistics & numerical data]; 10. Spinal Stenosis [*surgery]; 11. Treatment Outcome;
MESH terms:
Bioabsorbable versus metallic interference screws for graft fixation in anterior cruciate ligament reconstruction
1. *Absorbable Implants [adverse effects]; 2. *Anterior Cruciate Ligament Injuries; 3. *Bone Screws [adverse effects]; 4. Anterior Cruciate Ligament Reconstruction [instrumentation, *methods]; 5. Joint Instability [etiology]; 6. Knee Joint; 7. Metals [adverse effects]; 8. Patellar Ligament [transplantation]; 9. Randomized Controlled Trials as Topic; 10. Range of Motion, Articular; 11. Tendons [*transplantation]; 12. Treatment Outcome;
MESH terms:
Electrotherapy modalities for rotator cuff disease
1. *Rotator Cuff; 2. Diathermy [methods]; 3. Electric Stimulation Therapy [*methods]; 4. Magnetic Field Therapy [methods]; 5. Muscular Diseases [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Shoulder Pain [*therapy]; 8. Transcutaneous Electric Nerve Stimulation [methods]; 9. Ultrasonic Therapy [methods];
MESH terms:
Biologic interventions for fatigue in rheumatoid arthritis
1. Abatacept [therapeutic use]; 2. Adalimumab [therapeutic use]; 3. Antibodies, Monoclonal [therapeutic use]; 4. Antibodies, Monoclonal, Humanized [therapeutic use]; 5. Antirheumatic Agents [*therapeutic use]; 6. Arthritis, Rheumatoid [complications, *drug therapy]; 7. Certolizumab Pegol [therapeutic use]; 8. Etanercept [therapeutic use]; 9. Fatigue [*drug therapy, etiology, therapy]; 10. Immunosuppressive Agents [*therapeutic use]; 11. Infliximab [therapeutic use]; 12. Interferon‐gamma [antagonists & inhibitors]; 13. Randomized Controlled Trials as Topic; 14. Rituximab [therapeutic use];
MESH terms:
Non‐steroidal anti‐inflammatory drugs for chronic low back pain
1. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 2. Chronic Pain [*drug therapy]; 3. Diclofenac [therapeutic use]; 4. Disability Evaluation; 5. Ibuprofen [therapeutic use]; 6. Indomethacin [therapeutic use]; 7. Low Back Pain [*drug therapy]; 8. Pain Measurement; 9. Piroxicam [therapeutic use]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Surgery for Dupuytren's contracture of the fingers
1. Controlled Clinical Trials as Topic; 2. Dupuytren Contracture [*surgery]; 3. Fasciotomy; 4. Fingers [*surgery]; 5. Randomized Controlled Trials as Topic;
MESH terms:
High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis
1. *Exercise; 2. Arthralgia [therapy]; 3. Muscle Strength; 4. Osteoarthritis, Hip [*therapy]; 5. Osteoarthritis, Knee [*therapy]; 6. Pain Measurement; 7. Program Evaluation; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Radiofrequency denervation for chronic low back pain
1. Catheter Ablation [*methods]; 2. Chronic Pain [etiology, *surgery]; 3. Denervation [*methods]; 4. Low Back Pain [etiology, *surgery]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Intra‐articular corticosteroid for knee osteoarthritis
1. Adrenal Cortex Hormones [*administration & dosage, adverse effects]; 2. Arthralgia [*drug therapy, etiology]; 3. Hyaluronic Acid [administration & dosage, adverse effects, analogs & derivatives, therapeutic use]; 4. Injections, Intra‐Articular; 5. Osteoarthritis, Knee [*drug therapy, therapy]; 6. Pain Measurement; 7. Randomized Controlled Trials as Topic; 8. Therapeutic Irrigation [methods];
MESH terms:
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non‐radiographic axial spondyloarthritis)
1. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 2. Cohort Studies; 3. Cyclooxygenase 2 Inhibitors [therapeutic use]; 4. Indomethacin [adverse effects, therapeutic use]; 5. Naproxen [therapeutic use]; 6. Pain [drug therapy]; 7. Pain Measurement; 8. Randomized Controlled Trials as Topic; 9. Spondylarthritis [*drug therapy]; 10. Spondylitis, Ankylosing [*drug therapy];
MESH terms:
TNF‐alpha inhibitors for ankylosing spondylitis
1. Adalimumab; 2. Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 3. Antibodies, Monoclonal [therapeutic use]; 4. Antibodies, Monoclonal, Humanized [therapeutic use]; 5. Etanercept; 6. Immunoglobulin G [therapeutic use]; 7. Infliximab; 8. Randomized Controlled Trials as Topic; 9. Receptors, Tumor Necrosis Factor [therapeutic use]; 10. Spondylitis, Ankylosing [*drug therapy]; 11. Tumor Necrosis Factor‐alpha [*antagonists & inhibitors];
MESH terms:
Mobile bearing vs fixed bearing prostheses for posterior cruciate retaining total knee arthroplasty for postoperative functional status in patients with osteoarthritis and rheumatoid arthritis
1. *Knee Prosthesis; 2. Arthritis, Rheumatoid [*surgery]; 3. Arthroplasty, Replacement, Knee [adverse effects, *instrumentation, mortality]; 4. Bias; 5. Health Status; 6. Knee Joint; 7. Osteoarthritis, Knee [*surgery]; 8. Prosthesis Design [methods]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Range of Motion, Articular; 12. Reoperation [statistics & numerical data];
MESH terms:
Rituximab for rheumatoid arthritis
1. Antirheumatic Agents [*therapeutic use]; 2. Arthritis, Rheumatoid [*drug therapy]; 3. Drug Therapy, Combination [methods]; 4. Methotrexate [therapeutic use]; 5. Publication Bias; 6. Randomized Controlled Trials as Topic; 7. Rituximab [*therapeutic use];
MESH terms:
Exercise for osteoarthritis of the knee
1. *Exercise Therapy; 2. Arthralgia [rehabilitation]; 3. Osteoarthritis, Knee [*rehabilitation]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Sulfasalazine for ankylosing spondylitis
1. Antirheumatic Agents [*therapeutic use]; 2. Randomized Controlled Trials as Topic; 3. Spondylitis, Ankylosing [*drug therapy]; 4. Sulfasalazine [*therapeutic use];
MESH terms:
Uricosuric medications for chronic gout
1. Allopurinol [therapeutic use]; 2. Benzbromarone [therapeutic use]; 3. Chronic Disease; 4. Controlled Clinical Trials as Topic; 5. Gout [blood, *drug therapy]; 6. Probenecid [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Uric Acid [blood]; 9. Uricosuric Agents [adverse effects, *therapeutic use];
MESH terms:
Electrotherapy modalities for adhesive capsulitis (frozen shoulder)
1. Bursitis [*therapy]; 2. Electric Stimulation Therapy [*methods]; 3. Randomized Controlled Trials as Topic; 4. Shoulder Pain [*therapy];
MESH terms:
Interleukin‐1 inhibitors for acute gout
1. Acute Disease; 2. Antibodies, Monoclonal [*administration & dosage]; 3. Antibodies, Monoclonal, Humanized; 4. Gout [*drug therapy]; 5. Injections, Intramuscular; 6. Injections, Subcutaneous; 7. Interleukin‐1 [*antagonists & inhibitors]; 8. Randomized Controlled Trials as Topic; 9. Recombinant Fusion Proteins [*administration & dosage]; 10. Triamcinolone [administration & dosage];
MESH terms:
Manual therapy and exercise for adhesive capsulitis (frozen shoulder)
1. Bursitis [*therapy]; 2. Exercise Therapy [*methods]; 3. Glucocorticoids [therapeutic use]; 4. Injections, Intra‐Articular; 5. Musculoskeletal Manipulations [*methods]; 6. Randomized Controlled Trials as Topic; 7. Shoulder Pain [therapy];
MESH terms:
Diacerein for osteoarthritis
1. Anthraquinones [*therapeutic use]; 2. Anti-Inflammatory Agents, Non-Steroidal [*therapeutic use]; 3. Osteoarthritis [*drug therapy]; 4. Randomized Controlled Trials as Topic [standards];
MESH terms:
Self‐management education programmes for osteoarthritis
1. Health Literacy; 2. Osteoarthritis [*therapy]; 3. Pain Management [methods]; 4. Patient Education as Topic [*methods]; 5. Program Evaluation; 6. Randomized Controlled Trials as Topic; 7. Self Care [*methods];
MESH terms:
Rehabilitation following surgery for lumbar spinal stenosis
1. Leg; 2. Low Back Pain [etiology, *rehabilitation, surgery]; 3. Postoperative Care [*methods]; 4. Spinal Stenosis [complications, *rehabilitation, surgery]; 5. Time Factors;
MESH terms:
Lifestyle interventions for acute gout
1. *Life Style; 2. Acute Disease; 3. Anti‐Inflammatory Agents [therapeutic use]; 4. Colchicine [administration & dosage]; 5. Combined Modality Therapy [methods]; 6. Cryotherapy [methods]; 7. Drug Therapy, Combination [methods]; 8. Gout [*therapy]; 9. Gout Suppressants [administration & dosage]; 10. Prednisolone [administration & dosage]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Non‐pharmacological interventions for fatigue in rheumatoid arthritis
1. Arthritis, Rheumatoid [*complications]; 2. Diet, Mediterranean; 3. Exercise Therapy [methods]; 4. Fatigue [etiology, *therapy]; 5. Fatty Acids, Omega-3 [therapeutic use]; 6. Pain Management [methods]; 7. Psychotherapy [methods]; 8. Reflexotherapy;
MESH terms:
Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis
1. Anemia [blood, *drug therapy, etiology]; 2. Arthritis, Rheumatoid [blood, *complications]; 3. Epoetin Alfa; 4. Erythropoietin [adverse effects, *therapeutic use]; 5. Hematinics [adverse effects, *therapeutic use]; 6. Hemoglobin A [metabolism]; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [adverse effects, therapeutic use];
MESH terms:
Treatments for alopecia areata: a network meta‐analysis
1. *Alopecia Areata [drug therapy]; 2. Betamethasone; 3. *Biological Products; 4. *Cyclosporins; 5. Immunosuppressive Agents [therapeutic use]; 6. Minoxidil [therapeutic use]; 7. Network Meta-Analysis; 8. Prednisolone;
MESH terms:
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
1. *Biological Products [therapeutic use]; 2. Infliximab [therapeutic use]; 3. Methotrexate [therapeutic use]; 4. Network Meta-Analysis; 5. *Psoriasis [drug therapy]; 6. Systematic Reviews as Topic; 7. Tumor Necrosis Factor-alpha; 8. Ustekinumab [therapeutic use];
MESH terms:
Negative pressure wound therapy for treating pressure ulcers
1. Bandages; 2. *Negative-Pressure Wound Therapy [methods]; 3. *Pressure Ulcer [therapy]; 4. Surgical Wound Infection; 5. Ulcer;
MESH terms:
Silicone gel sheeting for treating keloid scars
1. Bandages; 2. *Keloid [therapy]; 3. Randomized Controlled Trials as Topic; 4. Silicone Gels [therapeutic use]; 5. Triamcinolone Acetonide; 6. Wound Healing;
MESH terms:
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus
1. Alginates; 2. Bandages; 3. Hydrogels; 4. *Iodine; 5. *Pilonidal Sinus [surgery]; 6. *Zinc Oxide;
MESH terms:
Pressure redistributing static chairs for preventing pressure ulcers
1. Bedding and Linens; 2. Beds; 3. Bias; 4. *Pressure Ulcer [prevention & control];
MESH terms:
Silicone gel sheeting for treating hypertrophic scars
1. Bandages; 2. *Cicatrix, Hypertrophic [therapy]; 3. *Silicone Gels [therapeutic use]; 4. Wound Healing;
MESH terms:
Botulinum toxin type A for facial wrinkles
1. Bias; 2. Botulinum Toxins, Type A [adverse effects, *therapeutic use]; 3. Dermal Fillers [therapeutic use]; 4. Face; 5. Placebos [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Skin Aging [*drug effects];
MESH terms:
Topical benzoyl peroxide for acne
1. Acne Vulgaris [complications, *drug therapy]; 2. Benzoyl Peroxide [*therapeutic use]; 3. Cicatrix [etiology, prevention & control]; 4. Dermatologic Agents [*therapeutic use]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings
1. *Hygiene; 2. Administration, Topical; 3. Emollients [*therapeutic use]; 4. Patient Satisfaction; 5. Pruritus [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Skin Care [*methods]; 8. Soaps [chemistry, therapeutic use]; 9. Wounds and Injuries [*prevention & control];
MESH terms:
Interventions for chronic palmoplantar pustulosis
1. Administration, Topical; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Antibodies, Monoclonal, Humanized [*therapeutic use]; 5. Chronic Disease; 6. Exanthema [*therapy]; 7. Phototherapy; 8. Psoriasis [*therapy]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Remission Induction; 12. Ultraviolet Rays; 13. Ustekinumab;
MESH terms:
Topical and device‐based treatments for fungal infections of the toenails
1. Administration, Topical; 2. Antifungal Agents [administration & dosage, *therapeutic use]; 3. Onychomycosis [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Lifestyle changes for treating psoriasis
1. *Life Style; 2. *Quality of Life; 3. Chronic Disease; 4. Exercise [*physiology]; 5. Obesity [complications, prevention & control]; 6. Pruritus [prevention & control, therapy]; 7. Psoriasis [prevention & control, *therapy]; 8. Randomized Controlled Trials as Topic; 9. Walking;
MESH terms:
Interventions for hand eczema
1. Calcineurin Inhibitors [therapeutic use]; 2. Eczema [*drug therapy]; 3. Emollients [therapeutic use]; 4. Immunosuppressive Agents [therapeutic use]; 5. Odds Ratio; 6. Pruritus [drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Severity of Illness Index; 9. Treatment Outcome;
MESH terms:
Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis
1. Administration, Oral; 2. Administration, Topical; 3. Biological Therapy; 4. Immunosuppressive Agents [therapeutic use]; 5. Phototherapy; 6. Psoriasis [*therapy]; 7. Treatment Outcome;
MESH terms:
Antistreptococcal interventions for guttate and chronic plaque psoriasis
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Ascorbic Acid [therapeutic use]; 3. Azithromycin [therapeutic use]; 4. Erythromycin [therapeutic use]; 5. Penicillin V [therapeutic use]; 6. Psoriasis [*drug therapy, microbiology, pathology]; 7. Randomized Controlled Trials as Topic; 8. Rifampin [therapeutic use]; 9. Streptococcal Infections [*drug therapy]; 10. Tonsillectomy; 11. Vitamins [therapeutic use];
MESH terms:
Risk assessment tools for the prevention of pressure ulcers
1. Incidence; 2. Pressure Ulcer [epidemiology, *prevention & control]; 3. Randomized Controlled Trials as Topic; 4. Risk Assessment [methods];
MESH terms:
Support surfaces for treating pressure ulcers
1. Bedding and Linens [*standards]; 2. Beds [*standards]; 3. Equipment Design; 4. Pressure Ulcer [*therapy]; 5. Randomized Controlled Trials as Topic; 6. Surface Properties; 7. Wound Healing;
MESH terms:
Education of healthcare professionals for preventing pressure ulcers
1. Health Personnel [*education]; 2. Incidence; 3. Pressure Ulcer [epidemiology, *prevention & control]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Foam dressings for treating pressure ulcers
1. *Bandages, Hydrocolloid; 2. Hydrogels [therapeutic use]; 3. Pressure Ulcer [*therapy]; 4. Randomized Controlled Trials as Topic; 5. Silicones; 6. Wound Healing;
MESH terms:
Systemic antibiotics for treating malignant wounds
1. *Odorants; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Anti‐Infective Agents [*therapeutic use]; 4. Double‐Blind Method; 5. Metronidazole [*therapeutic use]; 6. Neoplasms [*complications]; 7. Prospective Studies; 8. Soft Tissue Injuries [drug therapy, etiology]; 9. Wounds and Injuries [*drug therapy, etiology];
MESH terms:
Anabolic steroids for treating pressure ulcers
1. Off‐Label Use; 2. Oxandrolone [adverse effects, *therapeutic use]; 3. Pressure Ulcer [*drug therapy]; 4. Starch [therapeutic use]; 5. Stearic Acids [therapeutic use]; 6. Testosterone Congeners [adverse effects, *therapeutic use]; 7. Wound Healing;
MESH terms:
Scalpel versus electrosurgery for major abdominal incisions
1. *Electrosurgery [adverse effects]; 2. *Surgical Instruments; 3. *Wound Healing; 4. Abdominal Wall [*surgery]; 5. Blood Loss, Surgical; 6. Cicatrix [etiology]; 7. Operative Time; 8. Randomized Controlled Trials as Topic; 9. Surgical Wound Dehiscence [epidemiology, etiology]; 10. Surgical Wound Infection [epidemiology, etiology]; 11. Tissue Adhesions [etiology];
MESH terms:
Drugs for discoid lupus erythematosus
1. Acitretin [adverse effects, therapeutic use]; 2. Albuterol [therapeutic use]; 3. Calcineurin Inhibitors [therapeutic use]; 4. Dermatologic Agents [adverse effects, *therapeutic use]; 5. Fluocinonide [therapeutic use]; 6. Hydrocortisone [therapeutic use]; 7. Hydroxychloroquine [therapeutic use]; 8. Lupus Erythematosus, Discoid [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Tacrolimus [analogs & derivatives, therapeutic use]; 11. Treatment Outcome;
MESH terms:
Emollients and moisturisers for eczema
1. Adrenal Cortex Hormones [therapeutic use]; 2. Eczema [*drug therapy]; 3. Emollients [chemistry, *therapeutic use]; 4. Patient Satisfaction; 5. Randomized Controlled Trials as Topic; 6. Severity of Illness Index; 7. Symptom Flare Up;
MESH terms:
Wound drainage for lower limb arterial surgery
1. *Vascular Surgical Procedures; 2. Drainage [instrumentation, *methods]; 3. Groin; 4. Hematoma [epidemiology]; 5. Lower Extremity [*blood supply]; 6. Peripheral Arterial Disease [*surgery]; 7. Randomized Controlled Trials as Topic; 8. Reoperation [statistics & numerical data]; 9. Suction; 10. Surgical Wound Infection;
MESH terms:
Bed rest for pressure ulcer healing in wheelchair users
1. *Bed Rest; 2. *Wound Healing; 3. Pressure Ulcer [*therapy]; 4. Wheelchairs [*adverse effects];
MESH terms:
Antibiotics and antiseptics for pressure ulcers
1. Anti-Bacterial Agents [*therapeutic use]; 2. Anti-Infective Agents, Local [*therapeutic use]; 3. Apitherapy; 4. *Bandages, Hydrocolloid; 5. Iodophors [therapeutic use]; 6. Pressure Ulcer [*therapy]; 7. Randomized Controlled Trials as Topic; 8. Resins, Plant [therapeutic use]; 9. Wound Healing [*drug effects];
MESH terms:
Interventions for acne scars
1. *Needles; 2. Acne Vulgaris [*complications]; 3. Atrophy; 4. Catheter Ablation [*methods]; 5. Chemexfoliation [adverse effects, *methods]; 6. Cicatrix [pathology, *therapy]; 7. Cosmetic Techniques [instrumentation]; 8. Dermal Fillers [*therapeutic use]; 9. Hypertrophy; 10. Laser Therapy [adverse effects, *methods];
MESH terms:
Antibiotics and antiseptics for surgical wounds healing by secondary intention
1. Anti-Bacterial Agents [*therapeutic use]; 2. Anti-Infective Agents, Local [*therapeutic use]; 3. Iodine [therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Sucralfate [therapeutic use]; 6. Surgical Mesh; 7. *Surgical Procedures, Operative; 8. Surgical Wound Infection [drug therapy]; 9. Trimethoprim, Sulfamethoxazole Drug Combination [therapeutic use]; 10. Wound Healing [*drug effects]; 11. Zinc Oxide [therapeutic use];
MESH terms:
Surgical hand antisepsis to reduce surgical site infection
1. *General Surgery; 2. Anti‐Infective Agents, Local [*administration & dosage]; 3. Antisepsis [*methods]; 4. Colony Count, Microbial; 5. Hand [*microbiology]; 6. Hand Disinfection [*methods]; 7. Randomized Controlled Trials as Topic; 8. Surgical Wound Infection [epidemiology, *prevention & control];
MESH terms:
Anti‐TNF agents for paediatric psoriasis
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects, *therapeutic use]; 2. Etanercept [adverse effects, *therapeutic use]; 3. Psoriasis [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Tumor Necrosis Factor-alpha [*antagonists & inhibitors];
MESH terms:
Interventions for hidradenitis suppurativa
1. Anti-Bacterial Agents [therapeutic use]; 2. Anti-Inflammatory Agents [therapeutic use]; 3. Hidradenitis Suppurativa [*therapy]; 4. Intense Pulsed Light Therapy [methods]; 5. Laser Therapy [methods]; 6. Photochemotherapy [methods]; 7. Phototherapy [methods]; 8. Randomized Controlled Trials as Topic; 9. Tumor Necrosis Factor-alpha [antagonists & inhibitors];
MESH terms:
Wound‐care teams for preventing and treating pressure ulcers
1. Patient Care Team [*organization & administration]; 2. Pressure Ulcer [prevention & control, *therapy];
MESH terms:
Oral fumaric acid esters for psoriasis
1. Administration, Oral; 2. Arthritis, Psoriatic [drug therapy]; 3. Dermatologic Agents [adverse effects, therapeutic use]; 4. Fumarates [*administration & dosage, adverse effects]; 5. Methotrexate [therapeutic use]; 6. Psoriasis [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Severity of Illness Index;
MESH terms:
Negative pressure wound therapy for treating surgical wounds healing by secondary intention
1. *Surgical Procedures, Operative; 2. *Wound Healing; 3. Bandages; 4. Negative‐Pressure Wound Therapy [*methods]; 5. Pilonidal Sinus [surgery]; 6. Randomized Controlled Trials as Topic; 7. Surgical Wound Infection [*therapy];
MESH terms:
Interventions for rosacea
1. Anti‐Infective Agents [therapeutic use]; 2. Brimonidine Tartrate; 3. Cyclosporine [therapeutic use]; 4. Dermatologic Agents [*therapeutic use]; 5. Dicarboxylic Acids [therapeutic use]; 6. Doxycycline [therapeutic use]; 7. Ivermectin [therapeutic use]; 8. Metronidazole [therapeutic use]; 9. Ophthalmic Solutions [therapeutic use]; 10. Quinoxalines [therapeutic use]; 11. Randomized Controlled Trials as Topic; 12. Rosacea [*drug therapy]; 13. Tetracycline [therapeutic use];
MESH terms:
Preoperative skin antiseptics for preventing surgical wound infections after clean surgery
1. *Preoperative Care; 2. Anti‐Infective Agents, Local [*therapeutic use]; 3. Chlorhexidine [therapeutic use]; 4. Ethanol [therapeutic use]; 5. Iodine Compounds [therapeutic use]; 6. Povidone‐Iodine [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Surgical Wound Infection [*prevention & control];
MESH terms:
Interventions for vitiligo
1. Combined Modality Therapy [methods]; 2. Ginkgo biloba; 3. Lasers, Excimer [therapeutic use]; 4. PUVA Therapy [methods]; 5. Photosensitizing Agents [therapeutic use]; 6. Phototherapy [methods]; 7. Plant Extracts [therapeutic use]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Skin Pigmentation; 11. Skin Transplantation [methods]; 12. Steroids [administration & dosage]; 13. Vitiligo [*therapy];
MESH terms:
Repositioning for treating pressure ulcers
1. *Moving and Lifting Patients; 2. *Patient Positioning; 3. *Wound Healing; 4. Pressure Ulcer [*therapy];
MESH terms:
Negative pressure wound therapy for partial‐thickness burns
1. *Negative‐Pressure Wound Therapy; 2. *Wound Healing; 3. Burns [pathology, *therapy]; 4. Occlusive Dressings; 5. Randomized Controlled Trials as Topic; 6. Suction [instrumentation, methods];
MESH terms:
Recombinant human growth hormone for treating burns and donor sites
1. *Transplant Donor Site; 2. Anabolic Agents [therapeutic use]; 3. Body Surface Area; 4. Burns [*drug therapy, pathology]; 5. Human Growth Hormone [*therapeutic use]; 6. Oxandrolone [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recombinant Proteins [therapeutic use]; 9. Wound Healing [*drug effects];
MESH terms:
Removal of nail polish and finger rings to prevent surgical infection
1. *Hand Disinfection; 2. Bacteria [isolation & purification]; 3. Colony Count, Microbial; 4. Cosmetics [*adverse effects]; 5. General Surgery; 6. Hand [*microbiology]; 7. Jewelry [*microbiology]; 8. Lacquer [*microbiology]; 9. Nails [*microbiology]; 10. Nursing Staff; 11. Operating Room Technicians; 12. Randomized Controlled Trials as Topic; 13. Surgical Wound Infection [*prevention & control];
MESH terms:
Topical agents and dressings for fungating wounds
1. Anti‐Infective Agents, Local [*administration & dosage]; 2. Antineoplastic Agents [administration & dosage]; 3. Biological Dressings; 4. Disease Progression; 5. Metronidazole [administration & dosage]; 6. Odorants [*prevention & control]; 7. Ointments [administration & dosage]; 8. Phosphorylcholine [administration & dosage, analogs & derivatives]; 9. Randomized Controlled Trials as Topic; 10. Silver Compounds [administration & dosage]; 11. Skin Neoplasms [complications, *drug therapy]; 12. Skin Ulcer [*drug therapy]; 13. Wounds and Injuries [drug therapy];
MESH terms:
Pressure‐relieving devices for treating heel pressure ulcers
1. *Bedding and Linens; 2. *Heel; 3. Beds; 4. Foot Ulcer [etiology, *therapy]; 5. Orthotic Devices; 6. Patient Dropouts; 7. Pressure Ulcer [*therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Narrow‐band ultraviolet B phototherapy versus broad‐band ultraviolet B or psoralen‐ultraviolet A photochemotherapy for psoriasis
1. Photochemotherapy [*methods]; 2. Photosensitizing Agents [*therapeutic use]; 3. Psoriasis [*drug therapy, pathology]; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome; 6. Ultraviolet Therapy [*methods];
MESH terms:
Antibiotic prophylaxis for preventing burn wound infection
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Antibiotic Prophylaxis [adverse effects, *methods]; 3. Bandages; 4. Burns [*complications]; 5. Randomized Controlled Trials as Topic; 6. Silver Sulfadiazine [adverse effects, therapeutic use]; 7. Skin, Artificial; 8. Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use]; 9. Wound Infection [chemically induced, *prevention & control];
MESH terms:
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low‐ and middle‐income countries
1. Acamprosate; 2. *Alcoholism [prevention & control]; 3. Amitriptyline; 4. Developing Countries; 5. Disulfiram; 6. Mirtazapine; 7. Naltrexone; 8. Ondansetron; 9. Topiramate;
MESH terms:
Baclofen for alcohol use disorder
1. Acamprosate [adverse effects, therapeutic use]; 2. Alcohol Drinking [drug therapy]; 3. *Alcoholism [drug therapy]; 4. *Baclofen [adverse effects, therapeutic use]; 5. Chronic Disease; 6. Naltrexone [adverse effects, therapeutic use];
MESH terms:
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
1. Analgesics, Opioid [adverse effects]; 2. *Buprenorphine [adverse effects]; 3. Heroin [adverse effects]; 4. Methadone [adverse effects]; 5. *Opioid-Related Disorders [drug therapy]; 6. Pharmaceutical Preparations;
MESH terms:
Music therapy for people with substance use disorders
1. Anxiety [therapy]; 2. Bias; 3. Craving; 4. *Music Therapy; 5. *Substance-Related Disorders [therapy];
MESH terms:
Strategies to improve smoking cessation rates in primary care
1. Primary Health Care; 2. Randomized Controlled Trials as Topic; 3. Smoking [epidemiology]; 4. *Smoking Cessation [methods]; 5. Smoking Prevention; 6. Tobacco Use Cessation Devices;
MESH terms:
Interventions to reduce tobacco use in people experiencing homelessness
1. Bias; 2. Carbon Monoxide [analysis]; 3. Cognitive Behavioral Therapy; 4. Cotinine [analysis]; 5. Counseling [methods]; 6. Electronic Nicotine Delivery Systems; 7. *Ill-Housed Persons; 8. Life Style; 9. Randomized Controlled Trials as Topic; 10. Smoking [blood, *therapy]; 11. Smoking Cessation [*methods]; 12. Text Messaging; 13. Tobacco Use Cessation Devices;